中国临床药学杂志

参考文献

[1] ARNOLD M, SIERRA M S, LAVERSANNE M, et al. Global patterns and trends in colorectal cancer incidence and mortality[J].Gut, 2017, 66(4):683.

[2] SIEGEL R L, WAGLE N S, CERCEK A, et al. Colorectal cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(3):233.

[3] SIEGEL R L, MILLER K D, GODING SAUER A, et al. Colorectal cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(3):145.

[4] DENG Y H, LI X M. Fruquintinib and its use in the treatment of metastatic colorectal cancer[J]. Future Oncol, 2019, 15(22):2571.

[5] KARKKAINEN M J, PETROVA T V. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis[J]. Oncogene, 2000, 19(49):5598.

[6] RICCI-VITIANI L, PALLINI R, BIFFONI M, et al. Erratum:tumour vascularization via endothelial differentiation of glioblastoma stem-like cells[J]. Nature, 2011, 477:238.

[7] SHALABY F, ROSSANT J, YAMAGUCHI T P, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice[J]. Nature, 1995, 376(6535):62.

[8] SHIBUYA M. Vascular endothelial growth factor(VEGF)and its receptor(VEGFR)signaling in angiogenesis:a crucial target for anti-and pro-angiogenic therapies[J]. Genes Cancer, 2011,2(12):1097.

[9] SUN Q L, ZHOU J H, ZHANG Z, et al. Discovery of fruquintinib,a potent and highly selective small molecule inhibitor of VEGFR1, 2, 3 tyrosine kinases for cancer therapy[J]. Cancer Biol Ther,2014, 15(12):1635.

[10] REN Y X, SUN Q L, LONG J W, et al. Abstract 2089:evaluation of fruquintinib, a potent and selective oral VEGFR inhibitor,in combination with targeted therapies or immune checkpoint inhibitors in preclinical tumor models[J]. Cancer Res, 2017,77(13_Supplement):2089.

[11] GU Y, WANG J, LI K, et al. Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor fruquintinib(HMPL-013)and the prediction of its human pharmacokinetics[J].Cancer Chemother Pharmacol, 2014, 74(1):95.

[12] LI J, QIN S K, XU R H, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer:the FRESCO randomized clinical trial[J].JAMA, 2018, 319(24):2486.

[13] SHIRLEY M. Fruquintinib:first global approval[J]. Drugs,2018, 78(16):1757.

[14]陈璐璐,张利苹,李静文,等.程序性死亡受体1抑制剂联合呋喹替尼后线治疗转移性结直肠癌的临床疗效和安全性研究[J].中国全科医学, 2023, 26(18):2262.

[15]林静,王年飞,吴秀伟,等.呋喹替尼不良反应及其与疗效的相关性[J].医药导报, 2021, 40(7):943.

[16]林静.呋喹替尼毒副作用深化研究[D].合肥:安徽医科大学,2019.

[17]吕沁依.呋喹替尼在晚期结直肠癌中的疗效及安全性评价[D].南京:东南大学, 2021.

[18]张晓葳.呋喹替尼治疗标准方案失败晚期实体瘤的疗效分析[D].合肥:安徽医科大学, 2019.

[19]杨小冬,张桂芳,慕竹青,等.呋喹替尼治疗晚期结直肠癌起始剂量和疗效及不良反应探讨[J].社区医学杂志, 2022, 20(17):967.

[20] CAO J N, ZHANG J, PENG W, et al. A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1,-2, and-3 tyrosine kinases in Chinese patients with advanced solid tumors[J].Cancer Chemother Pharmacol, 2016, 78(2):259.

[21] DASARI A, LONARDI S, GARCIA-CARBONERO R, et al.Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer(FRESCO-2):an international, multicentre,randomised, double-blind, phase 3 study[J]. Lancet, 2023,402(10395):41.

[22] LU S, CHANG J H, LIU X Q, et al. Randomized, double-blind,placebo-controlled, multicenter phase II study of fruquintinib after two prior chemotherapy regimens in Chinese patients with advanced nonsquamous non?small-cell lung cancer[J]. J Clin Oncol, 2018, 36(12):1207.

[23]王成杰,李艳. 41例PD-1抑制剂联合呋喹替尼治疗晚期结直肠癌患者药物不良反应的护理[J].天津护理, 2023, 31(3):323.

[24] GUO Y, ZHANG W J, YING J E, et al. Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours:the dose-escalation and metastatic colorectal cancer cohort in the doseexpansion phases[J]. Eur J Cancer, 2023, 181:26.

[25] MA S C, CHEN R, DUAN L, et al. Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer:results of a single-arm, single-center, prospective, phase II clinical study[J].J Gastrointest Oncol, 2023, 14(2):1052.

[26] LU S, ZHOU J Y, NIU X M, et al. Fruquintinib with gefitinib as first-line therapy in patients carrying EGFR mutations with advanced non-small cell lung cancer:a single-arm, phase II study[J]. Transl Lung Cancer Res, 2021, 10(2):839.

[27] ZHANG Y, WANG Z X, SHEN L, et al. A phase Ib/II study of fruquintinib in combination with paclitaxel as the second-line therapy for advanced gastric cancer[J]. Cancer Commun, 2023,43(1):150.

[28]胡浪,林小玲,唐文军.呋喹替尼单药及联合PD-1抑制剂用于晚期转移性结肠癌后线治疗的疗效及安全性[J].实用医学杂志,2023, 39(15):1966.

[29] DAI Y H, SUN L, ZHUANG L, et al. Efficacy and safety of lowdose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer:a retrospective cohort study[J]. J Gastrointest Oncol, 2022, 13(2):722.

[30] DENG Y Y, ZHANG X Y, ZHU P F, et al. Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer:a real-world study[J]. Front Oncol, 2023, 13:1097911.

[31] SONG Y, QU T, ZHANG H G, et al. The real-world practice of fruquintinib for Chinese patients with metastatic colorectal cancer[J]. Cancer Manag Res, 2021, 13:6199.

[32] ZHANG Q, CHEN M F, WANG Z H, et al. Efficacy and safety comparison of regorafenib and fruquintinib in metastatic colorectal cancer-an observational cohort study in the real world[J]. Clin Colorectal Cancer, 2022, 21(3):e152.

[33] DING X M, LIU Y, ZHANG Y W, et al. Efficacy and safety of fruquintinib as third-or further-line therapy for patients with advanced bone and soft tissue sarcoma:a multicenter retrospective study[J]. Anticancer Drugs, 2023, 34(7):877.

[34] LAVACCHI D, ROVIELLO G, GUIDOLIN A, et al. Evaluation of fruquintinib in the continuum of care of patients with colorectal cancer[J]. Int J Mol Sci, 2023, 24(6):5840.

[35] SUN L Y, HUANG S L, LI D, et al. Efficacy and safety of fruquintinib plus PD-1 inhibitors versus regorafenib plus PD-1inhibitors in refractory microsatellite stable metastatic colorectal cancer[J]. Front Oncol, 2021, 11:754881.

[36] ZHANG W J, ZHANG Z Y, LOU S T, et al. Efficacy, safety and predictors of combined fruquintinib with programmed death-1inhibitors for advanced microsatellite-stable colorectal cancer:a retrospective study[J]. Front Oncol, 2022, 12:929342.

[37] JIANG F E, ZHANG H J, YU C Y, et al. Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer:an observational pilot study[J]. Neoplasma,2021, 68(4):861.

[38] National Cancer Institute. Common Terminology Criteria for Adverse Events(CTCAE)Version 5.0[EB/OL].(2017-11-27)[2024-05-08].https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf.

[39] LIU S, LU L, PAN F, et al. Real-world data:fruquintinib in treating metastatic colorectal cancer[J]. Oncol Res, 2022, 29(1):25.

[40]杨泽佩.针刺治疗手足综合征的前瞻性、开放性临床研究[D].北京:北京中医药大学, 2020.

[41] HUSSON O, JONES R L. Q-TWiST:what really matters to the cancer patient?[J]. Cancer, 2017, 123(12):2200.

[42] GELBER R D, GOLDHIRSCH A, COLE B F. Evaluation of effectiveness:q-TWiST. the international breast cancer study group[J]. Cancer Treat Rev, 1993, 19(Suppl A):73.